Victoza® (liraglutide) provides greater glycaemic control than SGLT-2 inhibitors

Vancouver, Canada (ots/PRNewswire) -

This material is intended for global medical media only.

This material is not approved for Canadian journalists or Canadian
audiences.

For journalistic assessment and preparation before publication.

New findings from a network meta-analysis show that treatment with
Victoza® (liraglutide) provides a greater HbA1c reduction and an
improved likelihood of reaching glycaemic goals compared to
sodium-glucose co-transporter 2 (SGLT-2) inhibitors in people with
type 2 diabetes who are inadequately controlled with metformin alone
or in combination with sulfonylurea, dipeptidyl peptidase-4 (DPP-4)
inhibitors or thiazolidinedione.[1] Findings were presented today at
the World Diabetes Congress of the International Diabetes Federation
(IDF) in Vancouver, Canada.

The meta-analysis evaluated the relative efficacy of Victoza® to
SGLT-2 inhibitors, including canagliflozin, empagliflozin and
dapagliflozin.[1] In an analysis of 17 randomised controlled trials
(RCTs), Victoza® demonstrated greater reductions in mean HbA1c
compared to all SGLT-2 inhibitors (placebo-adjusted mean change
-1.01%/-1.18% for Victoza® 1.2 mg/1.8 mg; -0.64%/-0.79% for
canagliflozin 100 mg/300 mg; -0.32%/-0.38% for dapagliflozin 5 mg/10
mg; -0.59%/-0.62% for empagliflozin 10 mg/25 mg).[1]

"In the absence of head-to-head trials, this analysis provides
valuable insight into the comparative outcomes with liraglutide
versus SGLT-2 inhibitors in people with type 2 diabetes uncontrolled
on oral antidiabetic treatments," said Maria Lorenzi, MSc, lead
author and research manager, Redwood Outcomes, CA, US.

The networks of evidence analysed to evaluate the relative
efficacy of Victoza® compared with approved SGLT-2 inhibitors were
based on available data from RCTs that were published when the
meta-analysis was initiated.

About network meta-analyses

In network meta-analyses (NMA), multiple treatments are included,
using data from trials that compare at least two of these treatments.
A NMA offers the advantage of being able to compare any treatments
included in the network, including those that have not been compared
directly, and, in the right circumstances, allows the full set of
treatments to be ranked.[2] As with any NMA, some of the indirect
comparisons in the Victoza® compared to SGLT-2 inhibitors NMA may be
biased due to differences in patient characteristics between trials,
most notably duration of diabetes, and the number of concomitant oral
antidiabetic drugs.

About Victoza®

Victoza® (liraglutide) is a human glucagon-like peptide-1 (GLP-1)
analogue with an amino acid sequence 97% similar to endogenous human
GLP-1. Like natural GLP-1, Victoza® works by stimulating the
beta-cells to release insulin and suppressing glucagon secretion from
the alpha cells only when blood sugar levels are high. Due to this
glucose-dependent mechanism of action, Victoza® is associated with a
low rate of hypoglycaemia.*[3] In addition, Victoza® reduces body
weight and body fat mass through mechanisms involving reduced
appetite and lowered energy intake.[3]

Victoza® was launched in the EU in 2009 and is commercially
available in more than 80 countries with more than three million
patient years of use in people with type 2 diabetes globally.[3],[4]
In Europe, Victoza® is indicated for treatment of adults with type 2
diabetes to achieve glycaemic control in combination with oral
glucose-lowering medicinal products and/or basal insulin when these,
together with diet and exercise, do not provide adequate glycaemic
control.[3]

*Hypoglycaemia has primarily been observed when Victoza® is
combined with a sulfonylurea or basal insulin.

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90
years of innovation and leadership in diabetes care. This heritage
has given us experience and capabilities that also enable us to help
people defeat other serious chronic conditions: haemophilia, growth
disorders and obesity. Headquartered in Denmark, Novo Nordisk employs
approximately 40,300 people in 75 countries and markets its products
in more than 180 countries. For more information, visit
novonordisk.com (http://www.novonordisk.com/), Facebook
(http://www.facebook.com/novonordisk), Twitter
(http://www.twitter.com/novonordisk), LinkedIn
(http://www.linkedin.com/company/novo-nordisk), YouTube.
(http://www.youtube.com/novonordisk)

Further information

Media: Katrine Sperling +45 4442 6718
krsp@novonordisk.com

Åsa Josefsson +45 3079 7708 aajf@novonordisk.com

Investors: Peter Hugreffe Ankersen +45 3075 9085
phak@novonordisk.com

Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com

Daniel Bohsen +45 3079 6376 dabo@novonordisk.com

Kasper Veje +45 3079 8519 kpvj@novonordisk.com

Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com

References

1. Lorenzi M, Ploug U, Langer J, et al. Liraglutide vs SGLT-2
inhibitors in people with type 2 diabetes: a network
meta-analysis. Presented at 23rd World Diabetes Congress,
Vancouver, BC, Canada; 30 November - 4 December 2015. Abstract
number 0226-P.
2. Jackson D, Barrett J, Rice S, et al. A design-by-treatment
interaction model for network meta-analysis with random
inconsistency effects. Stat Med. 2014; 33:3639-3654.
3. EMA. Victoza® EU Summary of Product Characteristics. Available at:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Produc
t_Information/human/001026/WC500050017.pdf Last accessed October
2015.
4. Internal Calculations based on IMS Midas Quantum data. September
2015.

ots Originaltext: Novo Nordisk A/S
Im Internet recherchierbar: http://www.presseportal.de